Pegylated-interferon alpha 2a treatment for chronic hepatitis C in patients on chronic haemodialysis
| Autor: | Ovidiu Golea, Mirela Danila, Ioan Sporea, Corina Vernic, Camelia Totolici, Roxana Sirli, Alina Popescu |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
Adult
Male medicine.medical_specialty Alpha interferon Alpha (ethology) Interferon alpha-2 Antiviral Agents Gastroenterology Polyethylene Glycols Chronic hepatitis Renal Dialysis Internal medicine medicine Humans In patient Chronic hemodialysis Hepatitis Dose-Response Relationship Drug biology business.industry Interferon-alpha General Medicine Hepatitis C Chronic Middle Aged medicine.disease Recombinant Proteins Discontinuation Treatment Outcome Immunology biology.protein Female Antibody business Rapid Communication |
| Zdroj: | World Journal of Gastroenterology. 12:4191 |
| ISSN: | 1007-9327 |
| Popis: | AIM: To evaluate the response to pegylated-interferon alpha 2a in chronic hepatitis C patients on chronic haemodialysis. METHODS: Ten patients with chronic C hepatitis were enrolled in this study. All had increased aminotransferases for more than 6 mo, positive antiHCV antibodies and positive PCR HCV-RNA. We administrated Peg-Interferon alpha 2a 180 μg/wk for 48 wk. After 12 wk of treatment we evaluated the biochemical and early virological response (EVR). At the end of the treatment we evaluated the biochemical response and 24 wk after the end of the treatment we evaluated the sustained virological response (SVR). We monitored the side-effects during the treatment. RESULTS: Two patients dropped out in the first 12 wk of treatment and 2 after the first 12 wk of treatment. After 12 wk of treatment, 7 out of 8 patients had biochemical response and EVR and 1 had biochemical response but persistent viremia. We had to reduce the dose of pegylated-interferon to 135 μg/wk in 2 cases. Three out of 6 (50%) patients had SVR 24 wk after the end of the treatment. Intention-to-treat analysis showed that 3 out of 10 patients (30%) had SVR. Side-effects occurred in most of the patients (flu-like syndrome, thrombocytopenia or leucopoenia), but they did not impose the discontinuation of treatment. CONCLUSION: After 12 wk of treatment with Peg-Interferon alpha 2a (40 ku) in patients on chronic haemodialysis with chronic C hepatitis, EVR was obtained in 87.5% (7/8) of the cases. SVR was achieved in 50% of the cases (3/6 patients) that finished the 48 wk of treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|